Key points are not available for this paper at this time.
Molecular heterogeneity, if it confers different risks to patients and is unaccounted for in the design of a randomized study, can result in a clinical trial that is underpowered and fails to detect a truly effective new therapy for cancer.
Betensky et al. (Wed,) studied this question.